Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

677
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
677

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STEC in the natural environment of Uruguay: genomic surveillance and environmental circulation in the framework of One Health.

Microbiology spectrum·2025
Same author

Concurrent ANNPE and vertebral T-cell lymphoma in a dog: A case report.

The Journal of small animal practice·2025
Same author

Spontaneous complexity in the dynamics of slow laboratory earthquakes.

Nature communications·2025
Same author

Patient-specific prediction of glioblastoma growth via reduced order modeling and neural networks.

Mathematical biosciences·2025
Same author

Beneficial effect of GABA-producing Lactiplantibacillus strain LPB145 isolated from cheese starters evaluated in anxiety- and depression-like behaviours in rats.

Beneficial microbes·2024
Same author

Elastic Instability behind Brittle Fracture.

Physical review letters·2024

Related Experiment Video

Updated: Sep 21, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.9K

T cell therapy against cancer: A predictive diffuse-interface mathematical model informed by pre-clinical studies.

G Pozzi1, B Grammatica1, L Chaabane2

  • 1MOX Laboratory, Department of Mathematics, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy.

Journal of Theoretical Biology
|June 1, 2022
PubMed
Summary

This study models cancer treatment response using a mathematical approach. Activating tumor vessels to increase T cells significantly enhances predicted therapeutic effects and tumor regression.

Keywords:
Cahn-HilliardKeller-SegelMRIProstate cancerT cell therapyTRAMP modelVessel activation

More Related Videos

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.2K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.9K

Related Experiment Videos

Last Updated: Sep 21, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.9K
Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.2K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.9K

Area of Science:

  • Computational biology
  • Mathematical oncology
  • Immunotherapy modeling

Background:

  • T cell therapy shows promise for solid cancers, but predicting T cell behavior is crucial for optimization.
  • Current methods lack robust predictive capabilities for T cell-mediated cancer therapy efficacy.

Purpose of the Study:

  • To develop and validate a mathematical model predicting the responsiveness of mouse prostate adenocarcinoma to T cell-based therapies.
  • To investigate the impact of tumor-associated vessel activation on T cell infiltration and therapeutic outcomes.

Main Methods:

  • A diffuse interface mathematical model (Cahn-Hilliard equation) coupled with Keller-Segel equations for immune dynamics was employed.
  • The model was parameterized using pre-clinical MRI data from the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model.
  • Finite element method simulations were used to analyze tumor growth dynamics and T cell concentrations.

Main Results:

  • The model successfully simulated tumor growth and T cell interactions within the prostate adenocarcinoma microenvironment.
  • Including tumor-associated vessel activation in the model predicted significantly higher therapeutic effects and tumor regression.
  • Simulated outcomes aligned with existing experimental data, validating the model's predictive power.

Conclusions:

  • The developed diffuse-interface mathematical model accurately predicts in vivo T cell behavior during cancer immunotherapy.
  • This work serves as a proof-of-concept for using predictive mathematical strategies to optimize cancer immunotherapy.
  • Mathematical modeling offers a powerful tool for enhancing the clinical implementation of T cell-based cancer therapies.